Literature DB >> 22109347

HIV infection, immunodeficiency, viral replication, and the risk of cancer.

Michael J Silverberg1, Chun Chao, Wendy A Leyden, Lanfang Xu, Michael A Horberg, Daniel Klein, William J Towner, Robert Dubrow, Charles P Quesenberry, Romain S Neugebauer, Donald I Abrams.   

Abstract

BACKGROUND: Few studies have compared cancer risk between HIV-infected individuals and a demographically similar HIV-uninfected internal comparison group, adjusting for cancer risk factors.
METHODS: We followed 20,775 HIV-infected and 215,158 HIV-uninfected individuals enrolled in Kaiser Permanente (KP) California for incident cancer from 1996 to 2008. Rate ratios (RR) were obtained from Poisson models comparing HIV-infected (overall and stratified by recent CD4 count and HIV RNA) with HIV-uninfected individuals, adjusted for age, sex, race/ethnicity, calendar period, KP region, smoking, alcohol/drug abuse, and overweight/obesity.
RESULTS: We observed elevated RRs for Kaposi sarcoma (KS; RR = 199; P < 0.001), non-Hodgkin lymphoma (NHL; RR = 15; P < 0.001), anal cancer (RR = 55; P < 0.001), Hodgkin lymphoma (HL; RR = 19; P < 0.001), melanoma (RR = 1.8; P = 0.001), and liver cancer (RR = 1.8; P = 0.013), a reduced RR for prostate cancer (RR = 0.8; P = 0.012), and no increased risk for oral cavity/pharynx (RR = 1.4; P = 0.14), lung (RR = 1.2; P = 0.15), or colorectal (RR = 0.9; P = 0.34) cancers. Lung and oral cavity/pharynx cancers were elevated for HIV-infected subjects in models adjusted only for demographics. KS, NHL, anal cancer, HL, and colorectal cancer had significant (P < 0.05) trends for increasing RRs with decreasing recent CD4. The RRs for lung and oral cavity/pharynx cancer were significantly elevated with CD4 < 200 cells/μL and for melanoma and liver cancer with CD4 < 500 cells/μL. Only KS and NHL were associated with HIV RNA.
CONCLUSION: Immunodeficiency was positively associated with all cancers examined except prostate cancer among HIV-infected compared with HIV-uninfected individuals, after adjustment for several cancer risk factors. IMPACT: Earlier antiretroviral therapy initiation to maintain high CD4 levels might reduce the burden of cancer in this population.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22109347      PMCID: PMC3237725          DOI: 10.1158/1055-9965.EPI-11-0777

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  46 in total

1.  Incidence of non-AIDS-defining cancer in antiretroviral treatment-naïve subjects after antiretroviral treatment initiation: an ACTG longitudinal linked randomized trials analysis.

Authors:  Supriya Krishnan; Jeffrey T Schouten; Denise L Jacobson; Constance A Benson; Ann C Collier; Susan L Koletar; Jorge Santana; Fred R Sattler; Ronald Mitsuyasu
Journal:  Oncology       Date:  2011-05-23       Impact factor: 2.935

2.  Elevated risk of lung cancer among people with AIDS.

Authors:  Anil K Chaturvedi; Ruth M Pfeiffer; Leonard Chang; James J Goedert; Robert J Biggar; Eric A Engels
Journal:  AIDS       Date:  2007-01-11       Impact factor: 4.177

3.  Increased incidence of hepatocellular carcinoma (HCC) in HIV-1 infected patients.

Authors:  Javier Murillas; Manuel Del Río; Melchor Riera; Pedro Vaquer; Ana Salas; María Leyes; M Angeles Ribas; María Peñaranda Vera; Concepcion Villalonga
Journal:  Eur J Intern Med       Date:  2005-04       Impact factor: 4.487

4.  Trends in cancer risk among people with AIDS in the United States 1980-2002.

Authors:  Eric A Engels; Ruth M Pfeiffer; James J Goedert; Phillip Virgo; Timothy S McNeel; Steven M Scoppa; Robert J Biggar
Journal:  AIDS       Date:  2006-08-01       Impact factor: 4.177

5.  Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals.

Authors:  Alina Burgi; Stephanie Brodine; Scott Wegner; Mark Milazzo; Mark R Wallace; Katherine Spooner; David L Blazes; Brian K Agan; Adam Armstrong; Susan Fraser; Nancy F Crum
Journal:  Cancer       Date:  2005-10-01       Impact factor: 6.860

6.  Role of uncontrolled HIV RNA level and immunodeficiency in the occurrence of malignancy in HIV-infected patients during the combination antiretroviral therapy era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort.

Authors:  Mathias Bruyand; Rodolphe Thiébaut; Sylvie Lawson-Ayayi; Pierre Joly; Annie Jeanne Sasco; Patrick Mercié; Jean Luc Pellegrin; Didier Neau; François Dabis; Philippe Morlat; Geneviève Chêne; Fabrice Bonnet
Journal:  Clin Infect Dis       Date:  2009-10-01       Impact factor: 9.079

7.  Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy.

Authors:  Jerry Polesel; Gary M Clifford; Martin Rickenbach; Luigino Dal Maso; Manuel Battegay; Christine Bouchardy; Hansjakob Furrer; Barbara Hasse; Fabio Levi; Nicole M Probst-Hensch; Patrick Schmid; Silvia Franceschi
Journal:  AIDS       Date:  2008-01-11       Impact factor: 4.177

8.  Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma.

Authors:  Gary M Clifford; Martin Rickenbach; Jerry Polesel; Luigino Dal Maso; Ingrid Steffen; Bruno Ledergerber; Andri Rauch; Nicole M Probst-Hensch; Christine Bouchardy; Fabio Levi; Silvia Franceschi
Journal:  AIDS       Date:  2008-10-18       Impact factor: 4.177

9.  When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study.

Authors:  Lauren E Cain; Roger Logan; James M Robins; Jonathan A C Sterne; Caroline Sabin; Loveleen Bansi; Amy Justice; Joseph Goulet; Ard van Sighem; Frank de Wolf; Heiner C Bucher; Viktor von Wyl; Anna Esteve; Jordi Casabona; Julia del Amo; Santiago Moreno; Remonie Seng; Laurence Meyer; Santiago Perez-Hoyos; Roberto Muga; Sara Lodi; Emilie Lanoy; Dominique Costagliola; Miguel A Hernan
Journal:  Ann Intern Med       Date:  2011-04-19       Impact factor: 25.391

10.  HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies.

Authors:  Antonella d'Arminio Monforte; Donald Abrams; Christian Pradier; Rainer Weber; Peter Reiss; Fabrice Bonnet; Ole Kirk; Matthew Law; Stephane De Wit; Nina Friis-Møller; Andrew N Phillips; Caroline A Sabin; Jens D Lundgren
Journal:  AIDS       Date:  2008-10-18       Impact factor: 4.632

View more
  110 in total

1.  Relationship of immunologic response to antiretroviral therapy with non-AIDS defining cancer incidence.

Authors:  Elizabeth L Yanik; Sonia Napravnik; Stephen R Cole; Chad J Achenbach; Satish Gopal; Dirk P Dittmer; Andrew F Olshan; Mari M Kitahata; Michael J Mugavero; Michael Saag; Richard D Moore; W Christopher Mathews; Peter Hunt; Joseph J Eron
Journal:  AIDS       Date:  2014-04-24       Impact factor: 4.177

Review 2.  Non-AIDS definings malignancies among human immunodeficiency virus-positive subjects: Epidemiology and outcome after two decades of HAART era.

Authors:  Pierluigi Brugnaro; Erika Morelli; Francesca Cattelan; Andrea Petrucci; Sandro Panese; Franklyn Eseme; Francesca Cavinato; Andrea Barelli; Enzo Raise
Journal:  World J Virol       Date:  2015-08-12

Review 3.  Human papillomavirus in the HIV-infected host: epidemiology and pathogenesis in the antiretroviral era.

Authors:  Cristina Brickman; Joel M Palefsky
Journal:  Curr HIV/AIDS Rep       Date:  2015-03       Impact factor: 5.071

4.  Head and neck diffuse large B cell lymphomas (HN-DLBCL) in human immunodeficiency virus (HIV) positive patients: long-term results in the highly active antiretroviral therapy (HAART) era.

Authors:  Francesca De Felice; Andrea Di Mino; Lavinia Grapulin; Maria Lusia Mistrulli; Daniela Musio; Vincenzo Tombolini
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-07-12       Impact factor: 2.503

5.  Human Immunodeficiency Virus (HIV)- and Non-HIV-Associated Immunosuppression and Risk of Cervical Neoplasia.

Authors:  Michael J Silverberg; Wendy A Leyden; Aileen Chi; Steven Gregorich; Megan J Huchko; Shalini Kulasingam; Miriam Kuppermann; Anna Seto; Karen K Smith-McCune; George F Sawaya
Journal:  Obstet Gynecol       Date:  2018-01       Impact factor: 7.661

6.  Epidemiology of head and neck squamous cell cancer among HIV-infected patients.

Authors:  Gypsyamber Dʼsouza; Thomas E Carey; William N William; Minh Ly Nguyen; Eric C Ko; James Riddell; Sara I Pai; Vishal Gupta; Heather M Walline; J Jack Lee; Gregory T Wolf; Dong M Shin; Jennifer R Grandis; Robert L Ferris
Journal:  J Acquir Immune Defic Syndr       Date:  2014-04-15       Impact factor: 3.731

7.  HIV viremia and incidence of non-Hodgkin lymphoma in patients successfully treated with antiretroviral therapy.

Authors:  Chad J Achenbach; Ashley L Buchanan; Stephen R Cole; Lifang Hou; Michael J Mugavero; Heidi M Crane; Richard D Moore; Richard H Haubrich; Satish Gopal; Joseph J Eron; Peter W Hunt; Benigno Rodriguez; Kenneth Mayer; Michael S Saag; Mari M Kitahata
Journal:  Clin Infect Dis       Date:  2014-02-12       Impact factor: 9.079

8.  Advanced stage at diagnosis and elevated mortality among US patients with cancer infected with HIV in the National Cancer Data Base.

Authors:  Anna E Coghill; Xuesong Han; Gita Suneja; Chun Chieh Lin; Ahmedin Jemal; Meredith S Shiels
Journal:  Cancer       Date:  2019-05-03       Impact factor: 6.860

Review 9.  Combination antiretroviral therapy and cancer risk.

Authors:  Álvaro H Borges
Journal:  Curr Opin HIV AIDS       Date:  2017-01       Impact factor: 4.283

10.  The impact of HIV viral control on the incidence of HIV-associated anal cancer.

Authors:  Elizabeth Y Chiao; Christine M Hartman; Hashem B El-Serag; Thomas P Giordano
Journal:  J Acquir Immune Defic Syndr       Date:  2013-08-15       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.